ClinicalTrials.gg
CompletedNCT00055029Updated Nov 9, 2026

Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis

An observational study in Retinoschisis, sponsored by National Eye Institute (NEI). Completed at 2 sites in United States. Open to participants aged 9 Months to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by National Eye Institute (NEI) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
351
Ages
9 Months to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Retinoschisis with a site in United States — 3 open to participants now, 3 under way, 1 of them phase 3. Retinoschisis · United States.

Started
2003
the only one that year
Observational
6 of 10
2 open now
Registered
1st of 10
by date
Lead sponsor
3 of 10
National Eye Institute (NEI)

Among the 10 studies in Retinoschisis with a site in United States, this one is the only one that started in 2003, is one of 6 observational ones, and was the 1st registered.

Retinoschisis

19 studies on the registry are indexed under Retinoschisis; 5 are open to participants now.

Browse Retinoschisis studies →

Open to participants now

3 of the 10 studies in Retinoschisis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Retinoschisis studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 9 Months to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Retinoschisis with a site in United States, or all of them as a file.
02

Study summary

This study will explore the causes and eye problems of X-linked juvenile retinoschisis (XLRS), an inherited disease that causes vision loss primarily in young males. The vision loss, which worsens over time, is a result of schisis, or splitting, of the layers of the retina (tissue that lines the back of the eye). A better understanding of why and how XLRS develops might lead to improved treatments.

Patients 9 months of age and older with XLRS and females who are suspected carriers of the gene responsible for the disease (such as the mother of the patient) may be eligible for this study. Other family members of patients also may be enrolled.

Patients will undergo the following tests and procedures:

  • Personal and family medical history to review past and current medical conditions and treatments, particularly regarding eye disease, and to construct a family tree.
  • Eye examination to assess visual acuity (eye chart test) and examine pupils, lens, retina, and eye movements. The pupils will be dilated with drops for this examination.
  • Photography of the retina to help evaluate the status of the retina.
  • Specialized eye tests to evaluate color vision, field of vision, and ability to see in the dark.
  • Electroretinogram (ERG) to examine what happens to the eyes after a flash of bright light. For this test, the patient sits in a dark room for 30 minutes with his or her eyes patched. Then, a small silver disk electrode is taped to the forehead, the eye patches are removed, the surface of the eye is numbed with eye drops and contact lenses are placed on the eyes. The patient looks inside a large empty bowl and then a light flashes, first in the dark and then with a light turned on inside the bowl. The contact lenses sense small electrical signals generated by the retina when the light flashes.
  • Blood test to examine DNA for genetic study of XLRS.

Family members will provide a blood sample for genetic study.

Read the detailed description

Objectives:

The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease. The specific primary objectives of this study are to:

  1. Investigate the relationship between genotype and phenotype in X-Linked Retinoschisis by correlating four phenotype severity classes with two classes of genotypes. This is the first step in developing a comprehensive genotypephenotype

    correlation.

  2. Characterize the anatomical and functional characteristics of retinoschisis to refine the phenotype scale and investigate and characterize specific XLRS1 mutations to generate a well-documented genotype-phenotype correlation map.

With the opportunity to study the genotypes and phenotypes of many affected males and the genotype of family members, a secondary objective of this study will be to develop a detailed pedigree for affected families. This information may be used to develop preliminary risk estimates for potential carrier females.

Study Population:

Up to 500 participants may enroll in this study. A minimum of 150 of participants are expected to be males diagnosed with X-Linked Retinoschisis. Participants may be recruited from the NIH and also from participating off-site locations. The quality of the genetic observation is directly proportional to the number of affected individuals and genetically-different families enrolled.

Design:

This natural history, multi-center, registry study to enroll males diagnosed with X-Linked Retinoschisis and the family members of affected individuals. Onsite affected males will undergo clinical examination and have their blood drawn for genotyping. Onsite unaffected participants will undergo eye examinations. Blood may also be drawn from the onsite unaffected participants but this is not required. Sites outside of NIH are participating as referral centers to accumulate the cohort. Offsite affected male participants will forward a blood sample and records from previous eye examinations to the NEI for review and analysis. Offsite unaffected participants will forward records from previous eye examinations and may provide a blood sample although this is not required.

Outcome Measures:

The primary outcome is the categorization of the proband s genotype and phenotype and determination of the relationship between the two.

03

Conditions studied

  • Retinoschisis

Keywords

  • Retinoschisis
  • Genomic DNA
  • Pedigree Analysis
  • Genetic Analysis
  • Macular Degeneration
  • Natural History
04

Who can participate

Ages eligible
9 Months to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Up to 500 participants may enroll in this study. A minimum of 150 of participants are expected to be males diagnosed with X-Linked Retinoschisis. Participants may be recruited from the NIH and also from participating off-site locations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible participants must satisfy one of the criteria below:

  • Male diagnosed with X-Linked Juvenile Retinoschisis (proband). A proband will be defined as the first X-Linked Juvenile Retinoschisis diagnosed male in a given family who contacts the NIH for participation in the study; or
  • Female who is a suspected carrier (i.e., mother of proband); or
  • Other relative of proband including affected and unaffected males and females.

The participant (or the participant s legal guardian) understands and signs this protocol s document and minor participants between the ages of 7 and 17 must provide assent.

Exclusion criteria

EXCLUSION CRITERIA:

Affected males will be ineligible for participation if:

  • The participant has a significant media opacity or other obstruction precluding a complete fundus examination including retinal photography.
  • The participant is unwilling or unable to contribute a blood sample for genotyping if there is not existing genetic analysis data from a documented family member.

Both affected and unaffected individuals will be ineligible for participation if:

  • The participant is younger than two years (seen at the NIH) or younger than nine months (participating offsite through medical record review and blood submission).
  • The participant is unable to cooperate with study procedures without anesthesia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
351 participants (actual)

Groups and cohorts

  • Affected males and family members

    Up to 500 participants, including a minimum of 150 males diagnosed with XLRS

06

What researchers measure

Primary outcomes

  1. Investigate the relationship between genotype and phenotype in X-Linked Retinoschisis by correlating four phenotype severity classes with two classes of genotypes. This is the first step in developing a comprehensive genotype-phenotype correlati...

    The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease.

    Time frame: ongoing

  2. Characterize the anatomical and functional characteristics of retinoschisis to refine the phenotype scale and investigate and characterize specific XLRS1 mutations to generate a well-documented genotype-phenotype correlation map.

    The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease.

    Time frame: ongoing

Secondary outcomes

  1. To develop a detailed pedigree for affected families.

    This information may be used to develop preliminary risk estimates for potential carrier females

    Time frame: ongoing

07

Study locations

2 sites
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
  • William Beaumont Hospital
    Rochester, Michigan 48309, United States
08

References and documents

09

Timeline

9 registry updates since Sep 25, 2026

Started May 2003 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2003
First posted
Feb 17, 2003
StartActual
May 19, 2003
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description
9 updates, last Nov 9, 2026
Show all 9 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  3. Nov 3, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 29, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  6. Oct 16, 2026
    Minor edits only
    + 1 other change: description
  7. Oct 13, 2026
    Minor edits only
    + 1 other change: description
  8. Oct 8, 2026
    Minor edits only
    + 1 other change: description
  9. Oct 2, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00055029
Responsible party
Sponsor
First posted
Feb 17, 2003
Start date
May 19, 2003
Last update
Nov 9, 2026

Study contacts

Laryssa A Huryn, M.D.
principal investigator · National Eye Institute (NEI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion